Skip to content
Ontario Rheumatology Association
  • Login
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory

ORA Meets with pCPA and CHLIA

Jane Purvis • Edition: Summer 2018

The ORA’s third party payers committee met with representatives from the panCanadian pharmaceutical alliance and the Canadian Life and Health Insurance Association in Toronto on May 14, 2018 to discuss creating panCanadian biologic criteria for both initiation and renewal of biologics. This would result in the same criteria for approvals and renewals regardless of location, occupation or payer and would lead to seamless transfer of biologic payment for patients as well as clarity for providers. The meeting was very productive and we look forwards to working both with governments and insurance companies towards this important goal. Given the reach of both pCPA and CLHIA, this would be a national strategy and would be the first of its kind in any treatment area. More news to come when available!

Other Articles in the Summer 2018 Newsletter

  • Canada's Drug Scene: National Pharmacare, Drug Shortages and More
  • Post a Locum or Apply for One!
  • OMA Section on Rheumatology Report
  • Communication Update
  • Emerging Rheumatologists of Ontario (ERO) Committee
Editions
  • Winter 2021
  • Fall 2020
  • Summer 2020
  • Winter 2020
  • Winter 2019
  • Fall 2019
  • Spring 2019
  • Winter 2018
  • Fall 2018
  • Summer 2018
  • Summer 2017
  • Spring 2017
  • Fall 2017
  • Archive
  • Meet the Speakers: ORA 20th Annual Scientific Meeting
Committees
Communications Informatics Models of Care OMA
Tags
Biosimilar CSDTH Models of Care OBRI OMA pCPA SADIE

Contributors

The ORA’s executive members are the core contributors to the newsletter. The ORA welcomes guest contributions to the newsletter from members-at-large and others in the rheumatology community.

Contributors
Ontario Rheumatology Association

© 2020 Ontario Rheumatology Association. All Rights Reserved. Website by Digital Chaos Inc.

  • About
  • Annual Awards
  • Events
  • EAP & Limited Use Codes
  • Exceptional Access Program
  • EAP Forms and Downloads
  • Limited Use Codes
  • Biosimilar Fact Sheet
  • NIHB Drug List
  • MOHLTC IVIG Request Form
  • Informatics
  • Members
  • Member Directory
  • Past Meeting Resources
  • Peer Mentor Forum
  • BecomeA Member
  • Renew Membership
  • News
  • Newsletters
  • Drug Shortages Info
  • Other Publications
  • Info Hub
  • Contact
  • Privacy